Dynamic quotes: Off
|
Company Description (as filed with the SEC)
In 2010, our Board of Directors approved the change in our fiscal year end from June 30 to December 31. The change became effective at the end of the quarter ended December 31, 2010. All references to “years”, unless otherwise noted, refer to the 12-month fiscal year, which prior to July 1, 2010, ended on June 30, and beginning with December 31, 2010, ends on December 31, of each year. General Information We were incorporated in 1989 and are a regenerative medicine company focused on the development of innovative cell therapies to repair or regenerate damaged or diseased tissues. We are developing patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. We believe ixmyelocel-T (the generic name for our multicellular therapy) is a disease modifying therapy with multi-functional properties including: tissue remodeling, immuno-modulation and the promotion of angiogenesis. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.91 |
| Quarterly EPS Est: | -0.12 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
2.11 |
Data is provided by Zacks Investment Research

